Member Info for Sangijuelas1

You mean the unchanged Blautix data that is now the basis for starting a P3 trial?

And you knew nothing about 0518.

How's the LFT that you said was the best in the world?

These peeps are doing the same with nanoparticles

Avacta better get a move on
https://www.sciencedirect.com/science/article/abs/pii/S0142961221001472#:~:text=Collectively%2C%20our%20results%20suggest%20that,and%20potentiates%20checkpoint%20inhibitor%20immunotherapy.

And Ophidian you really demonstrated your ignorance with 4D, you have no idea what they are doing with ICIs

Not statistically significant, anecdotal

And there is no need for dose escalation as you just start with the maximum dose

It doesn't matter. This is to evaluate the safety of the pro drug.
If they didn't have to demonstrate safety they could go straight to P2 like 4D can with their live biotherapeutics, which are given green flag to skip initial safety data collection

You do understand that the dose escalation study is to demonstrate safety.

It is not going to provide statistically significant efficacy data.

It's to find the safest high dose that will be taken into a trial with a larger cohort and with more emphasis on efficacy.

Will take a while.

It's massively overvalued. I would buy for long term hold but not at this price.

It's still got the phantom value of the LFT attached as despite what people say that's why most bought in

A fair valuation given the state of the biotech market at the moment would be around £100m Mcap

From the 260s to 68p is 75% drop

People think they can get rich overnight with Biotech’s. You can't, you need a lot of patience.

And you need to watch out for the companies looking to raise capital by getting small retail investors hooked

As you have only ever posted positive fluff on Tils in all of your 600 posts

Cloudy it's interesting that you opened an LSE account in June 2014, incidentally the same month and year that Tils got going.

Are you actually GC?

I did. There are no trials in progress.

So no reason to invest.

Prefer to invest in a company that is at least trying to get its drugs approved.

What are the near term catalysts?

If people had listened to me a year or so ago when I first started raising concerns they might have saved a lot of money

Where's the data for peer review and independent analysis Hannah?

4D and other companies are 80% down. I just invested in Evelo 75% down and so is Seres.

They are all due to release data and results from trials, which is the only thing that will lift a biotech in a bear market.

Ok Hannah

4D is battered. But I am still happy holding and buying.

The best thing I did was get out here when it was in the 80s.

What is it? 30p now in old money and still no trials.

What is a biotech without a trial?

That's a press release. Where is the trial registered or published?

How long was dosing for? It doesn't say

It was June last year they said they had signed a contract to set up P2

Still nothing